Abstract: Chronic immune thrombocytopenia (ITP) is a condition associated with significant morbidity
I. Introduction
Immune thrombocytopenic purpura (ITP) is also known as idiopathic thrombocytopenic purpura (Cooper and Bussel, 2006). It is an autoimmune disorder characterized by immunologic destruction of otherwise normal platelets most commonly occurring in response to an unknown stimulus. ITP may occur as primary or in association with other disorders (secondary) Cindy et al., 2011. The clinical course of ITP is usually chronic in adults. In cases of chronic ITP, serious bleeding is not expected even with significant thrombocytopenia. The mortality rate due to bleeding secondary to ITP is less than 1% (George , 2009 ), but it is associated with significant morbidity; however the management options are often unsatisfactory with a portion of patients exhibiting a refractory-relapsing disease path despite various lines of treatment including splenectomy (Alhossain et al ., 2012).
Corticosteroids are given as the first line of therapy in ITP cases with serious thrombocytopenia. Splenectomy is the standard care for cases that are non-responsive to corticosteroids. The rate of complete remission is 66% (British Committee No optimal treatment is currently available for patients with chronic ITP who were resistant to splenectomy (Murat et al., 2010) . It has been pointed out that vincristine could be more effective in splenectomized patients (Ries, 1976 
II.
Patients and methods
1-Study Site:
The 
5-Ethical consideration
Patients were invited to participate in the study on their full well and the steps and aim of the research were explained to participants before taking verbal consent. This study showed that the total number of patients was 29 patients ( 21 non splenctomized "group I" , 7 males , 14 females ; mean age +SD = 30.6 + 8.9 years, range 16 -45 years ) and (8 splenctomized patients "group 2" , 2 males and 6 females; mean age +SD = 31.7 + 10.8 years , range 23 -44 years. This table revealed that the mean platelet count was (11.3 + 6 x 10 9 /L) in "group I" before the vincristine therapy and increased to reach its maximum level after the fifth and six weeks of vincristine therapy (94.8 + 71.2 and 80 + 60.7 x 10 9 /L) respectively , and in "group II" was (17 + 4.53 X 10 9 /L ) and increased to (78.87+59.47 , 103.87+79.11 and 111.5+84.54) after the fourth, fifth and six weeks of vincristine therapy respectively. Before Vincristine treatment 11.3 + 6.1 P-value NS * ** ** ** ** Wilcoxon test was used NS: not significant, *: significant (p< 0.05), **: highly significant (p<0.001) Table 4 revealed that when the both groups were compared to each other, group II had a significantly increased mean platelet count than group I after the 4 th week of vincristine treatment with (p< 0.05) , while no significant differences could be detected after the 1st , 2nd ,3rd , 5 th and 6 th weeks of vincristine treatment (table 5 & figure 5 ) . Mann-Whitney U test was used NS: not significant, *: significant (p< 0.05) Table 5 shows that mean platelet count after 2 , 4 and 6 months of stoppage of vincristine treatment in group I were (68.67+62.9 , 62.095+63.63 and 61.86 +67.32) respectively , and in group II were (118+89.52 , 117.16+89.54 and 104.63+79.18) respectively (table 6 and figure 6 A&B) . Table 6 shows that there was statistically significant persistent increase of the mean platelet count after 2 , 4 and 6 months of stoppage of vincristine treatment when compared with the mean platelet count before the use of vincristin treatment in group I with (p<0.001 , p< 0.05 and p< 0.05 ) respectively and in group II with (p< 0.05 ) for all comparisons (table 6& figure 6 A and B) . Table 8 shows that there was higher mean value of platelet count was observed after 4 and 6 months of stoppage of vincristine treatment among group II than group I with no statistically significant difference, while there was statistically significant differences when they compared after 2 months of stoppage of vincristine with (p< 0.05) table 8).
III. Results

IV.
Discussion:
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder mediated by the production of autoantibodies directed against platelets Patients with primary immune thrombocytopenia (ITP) may require treatment to reduce the risk of serious bleeding if platelets remain consistently low. While approximately 70-80% of patients respond to an initial course of corticosteroids, relapse is common. For steroid-refractory patients, there is a choice between surgical splenectomy and further medical treatments, based on many factors including the patient's bleeding history, fitness for surgery, comorbidities, tolerance of adverse events, lifestyle and preferences (Stasi et al ., 2010) . Splenectomy is currently employed as a second line therapy; however it is ineffective in about 30-40% of the cases. Also these therapies present an increasing risk for opportunistic infection and post surgical complications during their treatment courses and adversely affect the overall outcomes (Stasi et al ., 2010) .
The decision whether to proceed to splenectomy or try other medical therapies in corticosteroidrefractory ITP patients remains patient-specific. Splenectomy has its risks (including perioperative and longterm risks), and relapse/non response are relatively common, but it offers the possibility of cure in the majority of patients. However, newer treatments may potentially allow splenectomy to be deferred for prolonged periods, as well as providing alternative treatment options for patients who fail splenectomy (Stasi et al ., 2010) . Currently, there is a trend towards a decreased rate of splenectomy in ITP (George, 2006) . Although a safe procedure in the vast majority of patients, complications include surgical mortality, thromboembolic events, and overwhelming sepsis, and the long-term effects remain poorly understood (Dolan et al, 2007) . With the emergence of alternative therapies, clinicians increasingly consider delaying splenectomy until later in the course of the disease to allow more time for spontaneous resolution (Cooper et al ., 2002 , George et al., 2003  and Kuter et al, 2008) . Thus, it is essential to evaluate the role of vincristine in treating (splenectomized and non splenectomized) refractory ITP patients who are resistant to corticosteroids therapy or who have contraindications to their use with no available other lines of treatment especially with higher costs of other lines of treatment as immunoglobulin and also to assess the long term (6 months) follow up platelet count after stoppage of vincristine treatment.
This study included twenty nine refractory ITP patients with maximum dose of corticosteroids and even after high dose of dexamethason ( 21 of them non-splenectomized "group I" and the remaining 8 splenectomized " group II") were treated with two-hour intravenous infusion of vincristine (1-2 mg) once a week for 6 weeks . In every patient, the platelet count was evaluated just before and after the infusion of vincristine , follow up of those patients for 6 months after stoppage of vincristine were evaluated by platelet count every 2 months . Patients with hepatitis and chronic liver diseases were excluded from this study.
The results of this study were in agreement with the majority of studies, which mostly showed a rise in the platelet count in refractory ITP patients treated with vincristine. This result found that the mean platelet count increased significantly among non splenectomzed patients after the use of vincristin , this in agreement with This study revealed that vincristine may be effective line of treatment in referactory splenectomized patients than non splenectomized patients and this differences was noted significantly after the 4 th week of vincristine treatment (p< 0.05) , more studies needed to confirm this result as no available studies compared those groups of patient . But it has been pointed out in Ries. (1976) that vincristine could be more effective in splenectomized patients.
In this study a persistent increase of the mean platelet count was observed in both groups of patients after stoppage of vincristine treatment for 6 months when compared with the mean platelet count before the use of vincristin treatment , these results were in agreement with Linares et al.( 1988) who reported that referactory ITP patients showed a return to normal platelet counts maintained for 3 months or longer after vincristine treatment.Also these results were partially in agreement with Manoharan. (1986) study who reported that Vincristine therapy appears to be therapeutically beneficial and can achieve sustained recovery of platelet count in patients with ITP of less than six months duration , in contrary to this result in which good response maintained up to 6 months after stoppage of vincristine therapy .This may be explained by that their patients were 10 patients only and they received vincristine at weekly intervals for 4 weeks only in contrary of our patients who received vincristine for 6 weeks . The duration of vincristine treatment may play a role in sustained recovery of platelet count and this point need more studies?
These results disagree with that of Kueh. (1982) who reported the duration of platelet response to vincristine without concomitant azathioprine therapy was less than 10 weeks in contrary to this result in which sustained recovery of platelet count maintained up to 6 months after stoppage of vincristine therapy .This may be explained by that their patients were 12 patients and they received weekly (1 mg) vincristine injections to a cumulative dose not greater than 3 mg, but in this study we use vincristine (1-2 mg) up to 6 weeks. The duration of vincristine treatment in addition of the cumulative dose of vincristine may play a role in sustained recovery of platelet count.
Higher mean value of platelet count was observed after 4 and 6 months of stoppage of vincristine treatment among splenectomized more than non splenectomized patients, this comparison was statistically significant after 2 months of stoppage of vincristine treatment (p< 0.05). It seems to be that splenectomized ITP patients may has sustained recovery of platelet after vincristine stoppage more than non splenectomized patients, more studies needed to confirm this result as no available studies compared those groups of patient V.
Conclusion:
Administration of vincristine to chronic corticosteroid refractory immune thrombocytopenia (ITP) patients result in increase platelet count to a significant level and could be used in situations requiring increase of the platelet count in patients who failed to response to maximum dose of corticosteroid-therapy and or splenectomy, especially with limited resources with no available other lines of treatment and also in patients who in need to do surgical intervention.
